Table 3.
TPOAb−TgAb− | TPOAb+TgAb− | TPOAb−TgAb+ | TPOAb+TgAb+ | |
---|---|---|---|---|
MEN | ||||
N (%) | 4,000 (68.9) | 800 (13.8) | 491 (8.5) | 511 (8.8) |
Central obesity | 1,719 (43.0) | 329 (41.1) | 213 (43.4) | 222 (43.4) |
Hypertension | 1,596 (39.9) | 335 (41.9) | 180 (36.7) | 202 (39.5) |
HYPERGLYCEMIA | ||||
IFG | 553 (13.8) | 104 (13.0) | 50 (10.2)a | 66 (12.9) |
IGT | 282 (7.0) | 61 (7.6) | 37 (7.5) | 41 (8.0) |
Pre-diabetes | 1,601 (40.0) | 319 (39.9) | 195 (39.7) | 203 (39.7) |
Diabetes | 599 (15.0) | 134 (16.8) | 84 (17.1) | 75 (14.7) |
DYSLIPIDEMIA | ||||
High TG | 1,432 (35.8) | 297 (37.1) | 170 (34.6) | 188 (36.8) |
High TC | 1,273 (31.8) | 266 (33.3) | 164 (33.4) | 162 (31.7) |
High LDL-C | 1,007 (25.2) | 215 (26.9) | 124 (25.3) | 136 (26.6) |
Low HDL-C | 602 (15.0) | 126 (15.8) | 76 (15.5) | 77 (15.1) |
WOMEN | ||||
N (%) | 8,000 (65.8) | 1,202 (9.9) | 1,588 (12.0) | 1,372 (11.3) |
Central obesity | 2,616 (32.7) | 388 (32.3) | 502 (31.6) | 443 (32.3) |
Hypertension | 2,214 (27.7) | 361 (30.0) | 423 (26.6) | 359 (26.2) |
HYPERGLYCEMIA | ||||
IFG | 742 (9.3) | 107 (8.9) | 149 (9.4) | 120 (8.7) |
IGT | 685 (8.6) | 112 (9.3) | 111 (7.0)b | 108 (7.9) |
Pre-diabetes | 2,927 (36.6) | 476 (39.6) | 554 (34.9) | 499 (36.4) |
Diabetes | 958 (12.0) | 142 (11.8) | 169 (10.6) | 147 (10.7) |
DYSLIPIDEMIA | ||||
High TG | 1,903 (23.8) | 276 (23.0) | 341 (21.5)c | 311 (22.7) |
High TC | 2,505 (31.3) | 414 (34.4)d | 490 (30.9) | 412 (30.0) |
High LDL-C | 1,676 (21.0) | 275 (22.9) | 356 (22.4) | 298 (21.7) |
Low HDL-C | 2,195 (27.4) | 310 (25.8) | 420 (26.4) | 383 (27.9) |
Data are presented as n (%).
P = 0.026,
P = 0.038,
P = 0.047,
P = 0.03 as compared with that of TPOAb−TgAb− group, and none of them was less than the adjusted cutoff value of P due to the multiple comparisons for statistical significance (0.05/3 = 0.017) in chi-square test.